Vitamin D supplementation to prevent acute respiratory infections : systematic review and meta-analysis of aggregate data from randomised controlled trials
BACKGROUND: A 2017 meta-analysis of data from 25 randomised controlled trials of vitamin D supplementation for the prevention of acute respiratory infections revealed a protective effect of the intervention. Since then, 20 new RCTs have been completed.
METHODS: Systematic review and meta-analysis of data from randomised controlled trials (RCTs) of vitamin D for ARI prevention using a random effects model. Pre-specified sub-group analyses were done to determine whether effects of vitamin D on risk of ARI varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration or dosing regimen. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and the ClinicalTrials.gov registry from inception to 1st May 2020. Double-blind RCTs of supplementation with vitamin D or calcidiol, of any duration, were eligible if they were approved by a Research Ethics Committee and if ARI incidence was collected prospectively and pre-specified as an efficacy outcome. Aggregate data, stratified by baseline 25(OH)D concentration, were obtained from study authors. The study was registered with PROSPERO (no. CRD42020190633).
FINDINGS: We identified 45 eligible RCTs (total 73,384 participants). Data were obtained for 46,331 (98.0%) of 47,262 participants in 42 studies, aged 0 to 95 years. For the primary comparison of vitamin D supplementation vs. placebo, the intervention reduced risk of ARI overall (Odds Ratio [OR] 0.91, 95% CI 0.84 to 0.99; P for heterogeneity 0.01). No statistically significant effect of vitamin D was seen for any of the sub-groups defined by baseline 25(OH)D concentration. However, protective effects were seen for trials in which vitamin D was given using a daily dosing regimen (OR 0.75, 95% CI 0.61 to 0.93); at daily dose equivalents of 400-1000 IU (OR 0.70, 95% CI 0.55 to 0.89); and for a duration of ≤12 months (OR 0.82, 95% CI 0.72 to 0.93). No significant interaction was seen between allocation to vitamin D vs. placebo and dose frequency, dose size, or study duration. Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (OR 0.97, 95% CI 0.86 to 1.09). Risk of bias within individual studies was assessed as being low for all but three trials. A funnel plot showed left-sided asymmetry (P=0.008, Egger's test).
INTERPRETATION: Vitamin D supplementation was safe and reduced risk of ARI, despite evidence of significant heterogeneity across trials. Protection was associated with administration of daily doses of 400-1000 IU vitamin D for up to 12 months. The relevance of these findings to COVID-19 is not known and requires investigation.
FUNDING: None.
| Errataetall: |
UpdateIn: Lancet Diabetes Endocrinol. 2021 Mar 30;:. - PMID 33798465 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2020) vom: 25. Nov. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 12.11.2023 published: Electronic UpdateIn: Lancet Diabetes Endocrinol. 2021 Mar 30;:. - PMID 33798465 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.07.14.20152728 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318355221 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318355221 | ||
| 003 | DE-627 | ||
| 005 | 20231225165201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.07.14.20152728 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1061.xml |
| 035 | |a (DE-627)NLM318355221 | ||
| 035 | |a (NLM)33269357 | ||
| 035 | |a (PII)2020.07.14.20152728 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jolliffe, David A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vitamin D supplementation to prevent acute respiratory infections |b systematic review and meta-analysis of aggregate data from randomised controlled trials |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Lancet Diabetes Endocrinol. 2021 Mar 30;:. - PMID 33798465 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: A 2017 meta-analysis of data from 25 randomised controlled trials of vitamin D supplementation for the prevention of acute respiratory infections revealed a protective effect of the intervention. Since then, 20 new RCTs have been completed | ||
| 520 | |a METHODS: Systematic review and meta-analysis of data from randomised controlled trials (RCTs) of vitamin D for ARI prevention using a random effects model. Pre-specified sub-group analyses were done to determine whether effects of vitamin D on risk of ARI varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration or dosing regimen. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and the ClinicalTrials.gov registry from inception to 1st May 2020. Double-blind RCTs of supplementation with vitamin D or calcidiol, of any duration, were eligible if they were approved by a Research Ethics Committee and if ARI incidence was collected prospectively and pre-specified as an efficacy outcome. Aggregate data, stratified by baseline 25(OH)D concentration, were obtained from study authors. The study was registered with PROSPERO (no. CRD42020190633) | ||
| 520 | |a FINDINGS: We identified 45 eligible RCTs (total 73,384 participants). Data were obtained for 46,331 (98.0%) of 47,262 participants in 42 studies, aged 0 to 95 years. For the primary comparison of vitamin D supplementation vs. placebo, the intervention reduced risk of ARI overall (Odds Ratio [OR] 0.91, 95% CI 0.84 to 0.99; P for heterogeneity 0.01). No statistically significant effect of vitamin D was seen for any of the sub-groups defined by baseline 25(OH)D concentration. However, protective effects were seen for trials in which vitamin D was given using a daily dosing regimen (OR 0.75, 95% CI 0.61 to 0.93); at daily dose equivalents of 400-1000 IU (OR 0.70, 95% CI 0.55 to 0.89); and for a duration of ≤12 months (OR 0.82, 95% CI 0.72 to 0.93). No significant interaction was seen between allocation to vitamin D vs. placebo and dose frequency, dose size, or study duration. Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (OR 0.97, 95% CI 0.86 to 1.09). Risk of bias within individual studies was assessed as being low for all but three trials. A funnel plot showed left-sided asymmetry (P=0.008, Egger's test) | ||
| 520 | |a INTERPRETATION: Vitamin D supplementation was safe and reduced risk of ARI, despite evidence of significant heterogeneity across trials. Protection was associated with administration of daily doses of 400-1000 IU vitamin D for up to 12 months. The relevance of these findings to COVID-19 is not known and requires investigation | ||
| 520 | |a FUNDING: None | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Camargo, Carlos A |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Sluyter, John D |e verfasserin |4 aut | |
| 700 | 1 | |a Aglipay, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Aloia, John F |e verfasserin |4 aut | |
| 700 | 1 | |a Ganmaa, Davaasambuu |e verfasserin |4 aut | |
| 700 | 1 | |a Bergman, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Borzutzky, Arturo |e verfasserin |4 aut | |
| 700 | 1 | |a Damsgaard, Camilla T |e verfasserin |4 aut | |
| 700 | 1 | |a Dubnov-Raz, Gal |e verfasserin |4 aut | |
| 700 | 1 | |a Esposito, Susanna |e verfasserin |4 aut | |
| 700 | 1 | |a Gilham, Clare |e verfasserin |4 aut | |
| 700 | 1 | |a Ginde, Adit A |e verfasserin |4 aut | |
| 700 | 1 | |a Golan-Tripto, Inbal |e verfasserin |4 aut | |
| 700 | 1 | |a Goodall, Emma C |e verfasserin |4 aut | |
| 700 | 1 | |a Grant, Cameron C |e verfasserin |4 aut | |
| 700 | 1 | |a Griffiths, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Hibbs, Anna Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Janssens, Wim |e verfasserin |4 aut | |
| 700 | 1 | |a Khadilkar, Anuradha Vaman |e verfasserin |4 aut | |
| 700 | 1 | |a Laaksi, Ilkka |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Margaret T |e verfasserin |4 aut | |
| 700 | 1 | |a Loeb, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Maguire, Jonathon L |e verfasserin |4 aut | |
| 700 | 1 | |a Majak, Paweł |e verfasserin |4 aut | |
| 700 | 1 | |a Mauger, David T |e verfasserin |4 aut | |
| 700 | 1 | |a Manaseki-Holland, Semira |e verfasserin |4 aut | |
| 700 | 1 | |a Murdoch, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Nakashima, Akio |e verfasserin |4 aut | |
| 700 | 1 | |a Neale, Rachel E |e verfasserin |4 aut | |
| 700 | 1 | |a Pham, Hai |e verfasserin |4 aut | |
| 700 | 1 | |a Rake, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Rees, Judy R |e verfasserin |4 aut | |
| 700 | 1 | |a Rosendahl, Jenni |e verfasserin |4 aut | |
| 700 | 1 | |a Scragg, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Dheeraj |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Yoshiki |e verfasserin |4 aut | |
| 700 | 1 | |a Simpson-Yap, Steve |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Geeta Trilok |e verfasserin |4 aut | |
| 700 | 1 | |a Urashima, Mitsuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Martineau, Adrian R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2020) vom: 25. Nov. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:25 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.07.14.20152728 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 25 |c 11 | ||